Marvel Biosciences Corp.
MRVL.V
TSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 173.30K | 175.80K | 171.20K | 154.70K | 229.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 355.70K | 176.10K | 371.70K | 163.00K | 241.80K |
| Operating Income | -355.70K | -176.10K | -371.70K | -163.00K | -241.80K |
| Income Before Tax | -866.30K | -181.10K | -341.70K | -203.80K | -432.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -866.30K | -181.10K | -341.70K | -203.80K | -432.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -866.30K | -181.10K | -341.70K | -203.80K | -432.10K |
| EBIT | -355.70K | -176.10K | -371.70K | -163.00K | -241.80K |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.02 | 0.00 | -0.01 | 0.00 | -0.01 |
| Normalized Basic EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| EPS Diluted | -0.02 | 0.00 | -0.01 | 0.00 | -0.01 |
| Normalized Diluted EPS | -0.01 | 0.00 | 0.00 | 0.00 | -0.01 |
| Average Basic Shares Outstanding | 52.97M | 46.73M | 44.79M | 44.79M | 40.50M |
| Average Diluted Shares Outstanding | 52.97M | 46.73M | 44.79M | 44.79M | 40.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |